ECO Animal Health Group (LON:EAH) Reaches New 1-Year High – Still a Buy?

ECO Animal Health Group plc (LON:EAH)’s stock price reached a new 52-week high during trading on Monday . The company traded as high as GBX 116.90 and last traded at GBX 114, with a volume of 97456 shares trading hands. The stock had previously closed at GBX 108.50.

Wall Street Analyst Weigh In

Separately, Shore Capital raised their price objective on shares of ECO Animal Health Group from GBX 150 to GBX 160 and gave the stock a “buy” rating in a report on Tuesday, December 2nd. One equities research analyst has rated the stock with a Buy rating, Based on data from MarketBeat, ECO Animal Health Group presently has an average rating of “Buy” and an average target price of GBX 160.

ECO Animal Health Group Trading Up 5.1%

The company’s 50-day moving average is GBX 98.97 and its 200-day moving average is GBX 85.23. The company has a debt-to-equity ratio of 4.81, a quick ratio of 2.14 and a current ratio of 2.96. The firm has a market cap of £76.48 million, a price-to-earnings ratio of 25.97 and a beta of -0.05.

ECO Animal Health Group (LON:EAH) last announced its earnings results on Monday, December 1st. The company reported GBX (0.54) earnings per share for the quarter. ECO Animal Health Group had a return on equity of 1.27% and a net margin of 1.17%.

Insiders Place Their Bets

In other news, insider David Hallas acquired 18,348 shares of the company’s stock in a transaction on Thursday, December 4th. The stock was purchased at an average cost of GBX 109 per share, with a total value of £19,999.32. 11.14% of the stock is owned by company insiders.

About ECO Animal Health Group

ECO Animal Health is a world leader in animal health, developing and marketing branded veterinary pharmaceuticals globally, with expertise in antibiotics and vaccines for pigs and poultry. We have a maturing proprietary R&D pipeline.

Headquartered in the UK, with global offices including R&D and manufacturing, we have marketing authorisations in over 70 countries and employ over 200 people worldwide.

Our lead product, Aivlosin® is a proprietary, patented medication which is effective against both respiratory and intestinal diseases in pigs and poultry.